Efficacy of toludesvenlafaxine in the treatment of patients with major depressive disorder with anhedonia
- VernacularTitle:托鲁地文拉法辛治疗伴快感缺失的重度抑郁症患者的疗效观察
- Author:
Wei LIU
1
;
Jie MA
2
;
Wenfeng QI
1
;
Hongjing SONG
1
;
Bing LI
3
Author Information
1. Dept. of the Second Clinical Psychology，Hebei Mental Health Center （the Sixth People’s Hospital of Hebei Province）/Hebei Key Laboratory for Major Mental and Behavioral Disorders/ the Sixth Clinical Medical College of Hebei University，Hebei Baoding 071000，China
2. Dept. of the Second Geriatric Psychiatry，Hebei Mental Health Center （the Sixth People’s Hospital of Hebei Province）/Hebei Key Laboratory for Major Mental and Behavioral Disorders/ the Sixth Clinical Medical College of Hebei University，Hebei Baoding 071000，China
3. Dept. of Psychiatry，Hebei Mental Health Center （the Sixth People’s Hospital of Hebei Province）/Hebei Key Laboratory for Major Mental and Behavioral Disorders/ the Sixth Clinical Medical College of Hebei University，Hebei Baoding 071000，China
- Publication Type:Journal Article
- Keywords:
toludesvenlafaxine;
major depressive disorder;
anhedonia;
efficacy;
safety
- From:
China Pharmacy
2026;37(12):1596-1600
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the efficacy and safety of toludesvenlafaxine in the treatment of patients with major depressive disorder （MDD） with anhedonia. METHODS This retrospective study included 160 patients with MDD with anhedonia who were treated at Hebei Mental Health Center from May 2023 to August 2025. These patients were divided into a control group （ n ＝81） and an observation group （ n ＝79） according to treatment regimens. All patients received transcranial magnetic stimulation therapy. On this basis，the control group was treated with Sertraline Hydrochloride Tablets， while the observation group received Toludesvenlafaxine Hydrochloride Sustained-Release Tablets，with an 8-week continuous treatment course.To compare t he clinical total effective rate， anhedonia remission rate，the severity of depressive symptoms，degree of anhedonia，cognitive function，social function and quality of life between the two groups before and after treatment， the incidence of adverse reactions during treatment was recorded simultaneously. RESULTS After treatment，the total effective rate and anhedonia remission rate of the observation group were significantly higher than the control group （ P ＜0.05）. At the 4th and 8th weeks of treatment， the scores of Snaith-Hamilton Pleasure Scale， Hamilton Depression Rating Scale-17 Items， and Sheehan Disability Scale of both groups were significantly lower than those before treatment in the same group， and the observation group was significantly lower than the control group （ P ＜0.05）； the scores of Montreal Cognitive Assessment and Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form were significantly higher than those before treatment in the same group， and the observation group was significantly higher than the control group （ P ＜0.05）. There was no statistically significant difference in the overall incidence of adverse reactions between the two groups （ P ＞0.05）. CONCLUSIONS Toludesvenlafaxine can significantly improve depressive symptoms， cognitive function， and social function in MDD patients with anhedonia，with good safety.
